Neuroscience
Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).
Speculations that Biogen might appeal the decision after reports of the company hiring several lobbyists, including Clyburn Consulting and Federal Street Strategies.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
Biogen has withdrawn its Marketing Authorization Application (MAA) for European approval of Aduhelm after regulators hinted data was not strong enough to support potential approval.
AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s Disease and other movement disorders.
The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.
INmune Bio has announced that it has dosed the first patient in its Phase II clinical trial of XPro1595 for the treatment of neuroinflammation as a cause of Alzheimer’s Disease.
New Haven, Conn.-based BioXcel Therapeutics launched a wholly-owned subsidiary, OnkosXcel, to focus on oncology.
Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.
PRESS RELEASES